Document:

EX-4.2

 Exhibit 4.2 

VEDANTRA PHARMACEUTICALS, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

August 30, 2018 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 1.
	 	 Definitions
	  	 	1	 
			
	 2.
	 	 Registration Rights
	  	 	4	 
			
		 	 2.1  Demand Registration
	  	 	4	 
			
		 	 2.2  Company Registration
	  	 	6	 
			
		 	 2.3  Underwriting Requirements
	  	 	6	 
			
		 	 2.4  Obligations of the Company
	  	 	8	 
			
		 	 2.5  Furnish Information
	  	 	9	 
			
		 	 2.6  Expenses of Registration
	  	 	9	 
			
		 	 2.7  Delay of Registration
	  	 	10	 
			
		 	 2.8  Indemnification
	  	 	10	 
			
		 	 2.9  Reports Under Exchange Act
	  	 	12	 
			
		 	 2.10  Limitations on Subsequent Registration Rights
	  	 	13	 
			
		 	 2.11  “Market Stand-off”
Agreement
	  	 	13	 
			
		 	 2.12  Restrictions on Transfer
	  	 	13	 
			
		 	 2.13  Termination of Registration Rights
	  	 	15	 
			
	 3.
	 	 Information Rights
	  	 	15	 
			
		 	 3.1  Delivery of Financial Statements
	  	 	15	 
			
		 	 3.2  Inspection
	  	 	17	 
			
		 	 3.3  Termination of Information Rights
	  	 	17	 
			
		 	 3.4  Confidentiality
	  	 	17	 
			
	 4.
	 	 Rights to Future Stock Issuances
	  	 	17	 
			
		 	 4.1  Right of First Offer
	  	 	17	 
			
		 	 4.2  Termination
	  	 	19	 
			
	 5.
	 	 Additional Covenants
	  	 	19	 
			
		 	 5.1  Insurance
	  	 	19	 
			
		 	 5.2  Employee Agreements
	  	 	19	 
			
		 	 5.3  Employee Stock
	  	 	20	 
			
		 	 5.4  Board Meetings
	  	 	20	 
			
		 	 5.5  Board Powers
	  	 	20	 
			
		 	 5.6  Directors’ Expenses
	  	 	21	 

							
			
		 	 5.7  D&O Insurance
	  	 	21	 
			
		 	 5.8  Director Indemnification; Successor Indemnification
	  	 	21	 
			
		 	 5.9  Qualified Small Business Stock
	  	 	21	 
			
		 	 5.10  Indemnification Matters
	  	 	22	 
			
		 	 5.11  Termination of Covenants
	  	 	22	 
			
	 6.
	 	 Miscellaneous
	  	 	22	 
			
		 	 6.1  Successors and Assigns
	  	 	22	 
			
		 	 6.2  Governing Law
	  	 	23	 
			
		 	 6.3  Counterparts; Facsimile
	  	 	23	 
			
		 	 6.4  Titles and Subtitles
	  	 	23	 
			
		 	 6.5  Notices
	  	 	23	 
			
		 	 6.6  Amendments and Waivers
	  	 	24	 
			
		 	 6.7  Severability
	  	 	24	 
			
		 	 6.8  Aggregation of Stock
	  	 	24	 
			
		 	 6.9  Subsequent Investors
	  	 	25	 
			
		 	 6.10  Entire Agreement
	  	 	25	 
			
		 	 6.11  Delays or Omissions
	  	 	25	 
			
		 	 6.12  Dispute Resolution
	  	 	25	 
			
		 	 6.13  Waiver of Jury Trial
	  	 	25	 
			
		 	 6.14  Acknowledgment
	  	 	26	 

  

					
	Schedule A	 	-	  	Investors
	Schedule B	 	-	  	Key Holders

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 30th day of August, 2018, by
and among Vedantra Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and
each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchasers (as defined in the Purchase Agreement) that becomes a party to this Agreement in
accordance with Section 6.9 hereof. 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred
Stock, $0.001 par value per share (the “Series A Preferred Stock”) and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to
that certain Investors’ Rights Agreement dated as of July 18, 2012, by and among the Company and such Existing Investors (the “Prior Agreement”); and 

WHEREAS, the Existing Investors are holders of at least a majority of the Registrable Securities of the Company (as defined in the
Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; and 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Investors to purchase shares of the
Company’s Series B Preferred Stock, $0.001 par value per share (the “Series B Preferred Stock” and, together with the Series A Preferred Stock and the Series B Preferred Stock, the “Preferred Stock”) pursuant
to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register Registrable Securities (as defined below) held by them, the rights of the Investors
to receive certain information from the Company and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement. 

NOW, THEREFORE, the parties, intending to be legally bound, hereby agree that the provisions of the Prior Agreement are hereby amended
and restated in their entirety as set forth herein, and hereby further agree, as follows 
 1. Definitions. For purposes of this
Agreement: 
 1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled
by one or more general partners or managing members of, or shares the same management company with, such Person. 
 1.2
“Board” means the Company’s Board of Directors. 

  
 - 1 - 

 1.3 “Common Stock” means shares of the Company’s common stock, par
value $0.01 per share. 
 1.4 “Damages” means any loss, damage, or liability (joint or several) to which a party hereto may
become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue
statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the
Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.5 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.6 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.7 “Excluded Registration”
means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 
 1.8 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.9 “Form S-3” means such form under the Securities Act as in effect on the date
hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.10 “GAAP” means generally accepted accounting principles in the United States. 

1.11 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.12 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

  
 - 2 - 

 1.13 “Initiating Holders” means, collectively, Holders who properly
initiate a registration request under this Agreement. 
 1.14 “IPO” means the Company’s first underwritten public
offering of its Common Stock under the Securities Act. 
 1.15 “Key Holder Registrable Securities” means (i) the
shares of Common Stock held by the Key Holders, (ii) the shares of Common Stock issuable upon exercise of stock options or restricted stock awards held by the Key Holders on the date hereof, (iii) the shares of Common Stock issuable upon
exercise of stock options or restricted stock awards granted to the Key Holders after the date hereof and (iv) any shares of Common Stock issued as, or issuable upon the conversion or exercise of any warrant, right, or other security that is
issued as a dividend or other distribution with respect to, or in exchange for or in replacement of, any of the securities referred to in the foregoing clause (i)-(iii) or this clause (iv). Notwithstanding the foregoing, in the event that any of the
securities referred to in the foregoing clauses (i)-(iv) are transferred other than in a manner permitted pursuant to the terms of this Agreement, such securities so transferred shall cease to be treated as Key Holder Registrable Securities for all
purposes of this Agreement. 
 1.16 “Major Investor” means any Investor that, individually or together with such
Investor’s Affiliates, holds at least 2,000,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.17 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.18 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.19 “Purchase Agreement” means that certain Series B Preferred Stock Purchase Agreement, dated of even date herewith,
by and among the Company and certain stockholders and investors of the Company as parties thereto, as amended and in effect from time to time. 

1.20 “Registrable Securities” means (i) shares of Common Stock issuable or issued upon conversion of the Preferred
Stock; (ii) any shares of Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iii) any shares of Common
Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses
(i) and (ii) above or in this clause (iii); excluding in all cases, however, (x) any Key Holder Registrable Securities and (y) any Registrable Securities, in either case if sold by a Person in a transaction in which the applicable
rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to
Section 2.13 of this Agreement. 

  
 - 3 - 

 1.21 “Registrable Securities then outstanding” means the number of shares
determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are
Registrable Securities. 
 1.22 “Restated Certificate” means the Company’s Amended and Restated Certificate of
Incorporation. 
 1.23 “Restricted Securities” means the securities of the Company required to bear the legend set forth in
Section 2.12(c) hereof. 
 1.24 “Sale of the Company” shall have the meaning ascribed to such
term in the Voting Agreement. 
 1.25 “SEC” means the Securities and Exchange Commission. 

1.26 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.27 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.28 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.29 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. 

1.30 “Subsequent Investor” means any Person that becomes a party to the Purchase Agreement after the date hereof and that
purchases shares of Series B Preferred Stock pursuant to, and in accordance with, the terms and conditions of the Purchase Agreement. 

1.31 “Voting Agreement” means that certain Amended and Restated Voting Agreement, dated of even date herewith, by and among
the Company and the stockholders of the Company as parties thereto, as amended and in effect from time to time. 
 2. Registration
Rights. The Company covenants and agrees as follows: 
 2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the date of this Agreement, the Company receives a
request from the Holder or Holders of at least a majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect

  
 - 4 - 

 
to outstanding Registrable Securities, then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”)
to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form
S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included
in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of
Section 2.1(c) and Section 2.3. 
 (b) Form
S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from the Holder or Holders of at least
twenty-five percent (25%) of the shares of the Registrable Securities then outstanding (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common
Stock) that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at
least $5 million then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event
within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to
be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of
Section 2.1(c) and Section 2.3. At the request of Holders of at least a majority of the shares of Registrable Securities then outstanding (subject to appropriate adjustment in the event of any
stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock) the Form S-3 registration statement with respect to the resale of outstanding Registrable Securities
of such Holders can be a shelf registration statement under Rule 415 of the Securities Act. 
 (c) Notwithstanding the foregoing
obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the
Company’s Board it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to
remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information
that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking
action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given;
provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other
stockholder during such ninety (90) day period. 

  
 - 5 - 

 (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Section 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty
(180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective and
has previously complied with all of its obligations under Section 2.2; (ii) after the Company has effected three (3) registrations pursuant to Section 2.1(a); or (iii) if the Initiating
Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall
not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of
filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such
registration statement to become effective and has previously complied with all of its obligations under Section 2.2; or (ii) if the Company has effected three (3) registrations pursuant to
Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this
Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration and elect not to pay the
registration expenses therefor, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d). 

2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for
stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give
each Holder and each Key Holder notice of such registration. Upon the request of each Holder and Key Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of
Section 2.3, cause to be registered all of the Registrable Securities and Key Holder Registrable Securities that each such Holder and Key Holder has requested to be included in such registration. The Company shall have the
right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder or Key Holder has elected to include Registrable Securities or
Key Holder Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s)
will be selected by the Company, provided that such underwriter(s) must be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable
Securities in such registration shall be conditioned upon such Holder’s participation in such 

  
 - 6 - 

 
underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such
underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision
of this Section 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so
advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities,
including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however,
that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in
accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities or Key Holder Registrable Securities in such underwriting unless the Holders or Key Holders accept the terms of the
underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of
securities, including Registrable Securities and Key Holder Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their
reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities and Key Holder Registrable
Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities and Key Holder Registrable
Securities requested to be registered can be included in such offering, then the Registrable Securities and Key Holder Registrable Securities that are included in such offering shall be allocated among the selling Holders and Key Holders in
proportion (as nearly as practicable to) the number of Registrable Securities and Key Holder Registrable Securities owned by each selling Holder and Key Holder or in such other proportions as shall mutually be agreed to by all such selling Holders
and Key Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the
foregoing, in no event shall (i) the number of Registrable Securities and Key Holder Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely
excluded from the offering, and (ii) the number of Registrable Securities and Key Holder Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless
such offering is the IPO, in which case the selling Holders and Key Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of
the provision in this Section 2.3(b) concerning apportionment, for any selling 

  
 - 7 - 

 
Holder and Key Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder or
Key Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder or Key
Holder,” and any pro rata reduction with respect to such “selling Holder or Key Holder” shall be based upon the aggregate number of Registrable Securities or Key Holder Registrable Securities owned by all Persons included in such
“selling Holder or key Holder,” as defined in this sentence. 
 (c) For purposes of Section 2.1, a
registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than fifty percent (50%) of the total number of Registrable
Securities that Holders have requested to be included in such registration statement are actually included. 
 2.4 Obligations of the
Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time
equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable
Securities that are intended to be offered on a continuous or delayed basis (including pursuant to SEC Rule 415), subject to compliance with applicable SEC rules, the Company will keep the registration statement effective until all such Registrable
Securities are sold or the Holders of a majority of the shares of Registrable Securities included in such registration statement request that the Company no longer maintain the effectiveness of such registration statement; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

  
 - 8 - 

 (e) in the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f) use its
commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which
similar securities issued by the Company are then listed; 
 (g) provide a transfer agent and registrar for all Registrable Securities
registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 
 (i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 (j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration statement covering
a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule
10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent to
the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself,
the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including 

  
 - 9 - 

 
all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one special
counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun
pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such
expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration) provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in
the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to
pay any of such expenses. All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities
registered on their behalf. 
 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining
or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each
selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of
the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon 

  
 - 10 - 

 
actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and
each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as
such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement
is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections
2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any
action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified
parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying
party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in
any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or
decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by 

  
 - 11 - 

 
reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by
the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case,
(x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event
shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses) paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall
survive the termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information, as
those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and
such other reports and documents so filed by the Company; 

  
 - 12 - 

 
and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without
registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would provide to such holder the right to
include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of
Registrable Securities that they wish to so include or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder, provided that this limitation shall
not apply to any Subsequent Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 
 2.11
“Market Stand-off” Agreement. Each Holder and Key Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period
commencing on the date of the final prospectus relating to the IPO, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days), (i) lend; offer; pledge; sell; contract
to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or
otherwise. The foregoing provisions of this Section 2.11 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers,
directors and all stockholders individually owning more than five percent (5%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same
restrictions. The underwriters in connection with such registration are intended third party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they
were a party hereto. Each Holder and Key Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or
that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based
on the number of shares subject to such agreements. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer 

  
 - 13 - 

 
instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance
with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to
the provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate or instrument representing (i) the
Preferred Stock, (ii) the Registrable Securities or Key Holder Registerable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend,
recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c) The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the
provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, such
holder thereof shall give notice to the Company of such holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail
and, if reasonably requested by the Company, shall be accompanied at such holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to
the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such
Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that
the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted
Securities in accordance with the terms of the notice given to the Company. The 

  
 - 14 - 

 
Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144, or (y) in any transaction in which such holder
transfers Restricted Securities to an Affiliate; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate or instrument evidencing the Restricted Securities
transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate shall not bear such
restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 Termination of Registration Rights. The right of any Holder or Key Holder to request registration or inclusion of Registrable
Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate; 

(b) when all of such Holder’s Registrable Securities or Key Holder’s Key Holder Registrable Securities could be sold without
restriction under SEC Rule 144 or another similar exemption; and 
 (c) the fifth (5th) anniversary of the IPO. 

3. Information Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor; provided that the Board has not
reasonably determined that such Major Investor is a competitor of the Company: 
 (a) as soon as practicable, but in any event within one
hundred twenty (120) days after the end of each fiscal year of the Company, (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual
amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Section 3.1(e)) for such year, and (iii) a statement of stockholders’
equity as of the end of such year, all such financial statements audited by independent public accountants of regionally recognized standing selected by the Board; 

(b) as soon as practicable, but in any event within forty five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance
with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments, and (ii) not contain all notes thereto that may be required in accordance with GAAP; 

(c) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock
issuable upon conversion or exercise of any outstanding securities convertible or exercisable 

  
 - 15 - 

 
for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any,
all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being true, complete, and
correct; 
 (d) as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income
statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be
subject to normal year-end audit adjustments, (ii) not contain all notes thereto that may be required in accordance with GAAP, (iii) no determination has been made for (A) the classification of
Series A Preferred Stock and accounting for potential tranche liabilities, (B) the existence of embedded derivatives or beneficial conversions of convertible debt, (C) accounting issues related to founders’ stock; and (iv) 2018 stock
compensation expense will be calculated as part of the year-end audit); 
 (e) as soon as
practicable, but in any event thirty (30) days before the end of each fiscal year, a comprehensive budget and business plan for the next fiscal year forecasting the Company’s revenues, expenses and cash position on a month-to-month basis for the upcoming fiscal year (collectively, the “Budget”), approved by the Board and prepared on a monthly basis, including balance
sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; 

(f) with respect to the financial statements called for in Section 3.1(a), Section 3.1(b)
and Section 3.1(d), an instrument executed by the chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared in accordance with GAAP consistently applied with
prior practice for earlier periods (except as otherwise set forth in Section 3.1(b) and Section 3.1(d) and fairly present the financial condition of the Company and its results of operation for the periods specified therein; and 

(g) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major
Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information (i) that the Company reasonably determines in good
faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or (ii) the disclosure of which would adversely affect the attorney-client privilege between
the Company and its counsel. 
 If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the
Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information
set forth in this Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement

  
 - 16 - 

 
if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this
Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2 Inspection. The Company shall permit each Major Investor (provided that the Board has not reasonably determined that such Major
Investor is a competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its
officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to
any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would
adversely affect the attorney-client privilege between the Company and its counsel. 
 3.3 Termination of Information Rights. The
covenants set forth in Section 3.1 and Section 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of an IPO, (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs first. 

3.4 Confidentiality. Each Holder and Key Holder party to this Agreement agrees that such Person will keep confidential and will not
disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file
a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such Investor), (b) is or has been
independently developed or conceived by such Person without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Person by a third party without a breach of any obligation of confidentiality
such third party may have to the Company; provided, however, that a Holder or Key Holder may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain
their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Person, if such prospective purchaser agrees to be bound by the provisions of this
Section 3.4; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Holder or Key Holder in the ordinary course of business, provided that such Holder
or Key Holder informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Holder or Key Holder
promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
 4.
Rights to Future Stock Issuances. 
 4.1 Right of First Offer. Subject to the terms and conditions of this
Section 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the 

  
 - 17 - 

 
Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates
in such proportions as it deems appropriate. 
 (a) The Company shall give notice (the “Offer Notice”) to each Major
Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor bears to the total Common Stock then
outstanding (assuming, for purposes of this sentence, full conversion into Common Stock of all Preferred Stock outstanding). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to
purchase or acquire all the New Securities available to it for purchase pursuant to the immediately preceding sentence (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten
(10) day period commencing after the Company has given such notice to the Fully Exercising Investors, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of New Securities
that such Fully Exercising Investor has already elected to purchase or acquire pursuant to this Section 4.1(b), a portion of the New Securities that were offered pursuant to this Section 4.1(b), but for which no
elections to purchase or acquire were made pursuant to this Section 4.1(b) by those Major Investors that are not Fully Exercising Investors with respect to such New Securities (the “Remaining Available New
Securities”), which portion shall be determined in the manner set forth below in this Section 4.1(b). The Remaining Available New Securities shall be allocated among those Fully Exercising Investors that have submitted written
elections to purchase or acquire a portion of such Remaining Available New Securities pursuant to this Section 4.1(b) (the “Oversubscribing Investors”) in accordance with such written elections;
provided, however, that if the number or amount of such Remaining Available New Securities is not sufficient to satisfy in full such written elections, then the Remaining Available New Securities shall be allocated (i) first, among the
Oversubscribing Investors in accordance with such written elections but only up to their respective Oversubscription Pro Rata Share (as defined below) of such Remaining Available New Securities and (ii) second, among those Oversubscribing
Investors that submitted pursuant to this Section 4.1(b) elections to purchase or acquire a portion of such Remaining Available New Securities in excess of the number or amount of such Remaining Available New Securities
allocated to them pursuant to the foregoing clause (i), which allocation pursuant to this clause (ii) to such Oversubscribing Investors shall be ratable in proportion to their respective Oversubscription Pro Rata Share. For purposes of this
Section 4.1(b), the term “Oversubscription Pro Rata Share” shall mean, with respect to each Oversubscribing Investor and any Remaining Available New Securities, that portion of such Remaining Available New
Securities that is equal to the product of such Remaining Available New Securities multiplied by a fraction, the numerator of which is equal to the Common Stock then held by such Oversubscribing Investor and the denominator of which is equal to the
total Common Stock then held by all Oversubscribing Investors (assuming, for purposes of this fraction, full conversion into Common Stock of all shares of Preferred Stock then held by all of the Oversubscribing Investors). The closing of any sale
pursuant to this Section 4.1(b) shall occur 

  
 - 18 - 

 
within the later of thirty (30) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c).
Notwithstanding anything express or implied in this Section 4 to the contrary, no Major Investor shall have any obligation to consummate any purchase of New Securities unless all of the New Securities are sold by the
Company and the sale of the New Securities occurs within the time periods contemplated under this Section 4. 

(c) The Company may, during the ninety (90) day period following the expiration of the periods provided in
Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to such Person or Persons than, those specified in
the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder
shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Section 4.1. 

(d) The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as
defined in the Restated Certificate); (ii) shares of Common Stock issued in the IPO; (iii) Common Stock or Derivative Securities issued in connection with an acquisition or strategic partnership transaction not primarily for the purpose of
capital raising which is approved by the Board, and (iv) shares of Common Stock or Derivative Securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment
leasing or real property leasing transaction approved by the Board. 
 4.2 Termination. The covenants set forth in
Section 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the Qualified Initial Public Offering, as such term is defined in the Restated Certificate, (ii) when the
Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs
first. 
 5. Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to maintain, from financially sound and reputable insurers,
liability, fire, property and casualty insurance policies currently in place with coverage in such amounts reasonably acceptable to the Board. 

5.2 Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged
by the Company or any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement, and (ii) each employee to enter into a one (1) year noncompetition and nonsolicitation
agreement, in the case of each of the agreements referenced in the foregoing items (i) and (ii) substantially in the form approved by the Board. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or
in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without prior approval by the Board. 

  
 - 19 - 

 5.3 Employee Stock. Unless otherwise approved by the Board, all employees and
consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing
for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly
installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in
Section 2.11. In addition, unless otherwise approved by the Board, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase
unvested shares at cost upon termination of employment of a holder of restricted stock. 
 5.4 Board Meetings. Unless otherwise
determined by the Board the Board shall meet at least quarterly during each full calendar year. 
 5.5 Board Powers. The management
of the business and the conduct of the affairs of the Company shall be vested in the Board, subject to the applicable protective provisions contained in the Restated Certificate in favor of the holders of Preferred Stock. The Company shall not take
any of the following actions without the approval of the Board: 
 (a) make, or permit any subsidiary to make, any loan or advance to, or
own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company, other than trade credit incurred in the ordinary course of business; 

(b) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the
Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board; 

(c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d) make any investment inconsistent with any
investment policy approved by the Board; 
 (e) incur any aggregate indebtedness that is not already included in a budget approved by the
Board, other than trade credit incurred in the ordinary course of business; 
 (f) otherwise enter into or be a party to any transaction
with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except for transactions contemplated by
this Agreement, the Purchase Agreement, and the Transaction Agreements (as defined in the Purchase Agreement); 
 (g) hire, terminate, or
change the compensation of the executive officers, including approving any option grants or stock awards to executive officers; 

  
 - 20 - 

 (h) change the principal business of the Company, enter new lines of business, or exit the
current line of business; 
 (i) sell, assign, license, pledge, or encumber material technology or intellectual property, other than
licenses granted in the ordinary course of business; or 
 (j) enter into any corporate strategic relationship involving the payment,
contribution, or assignment by the Company or to the Company of money or assets greater than $100,000. 
 5.6
Directors’ Expenses. The Company shall promptly reimburse each non-employee director for all reasonable
out-of-pocket costs, including but not limited to reasonable travel expenses, incurred by such non-employee director in
connection with his or her duties as a director. 
 5.7 D&O Insurance. The Company shall purchase and maintain Directors and Officers
liability insurance coverage with responsible and reputable insurance companies or associations naming each of the Company’s officers and directors as named insureds thereon. Such insurance coverage shall be in form and amounts as determined by
the Board. 
 5.8 Director Indemnification; Successor Indemnification. The Company shall take such actions as are necessary to ensure
that the Restated Certificate or Bylaws of the Company, as in effect from time to time, shall at all times provide for the exculpation and indemnification of members of the Board to the fullest extent permitted by law, including the limitation of
director liability and the payment of attorney’s fees. In the event of a Sale of the Company, to the extent necessary and appropriate, the parties hereto shall use commercially reasonable efforts to require that the successors and assigns of
the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Restated
Certificate, or elsewhere, as the case may be. Each director shall enter into a separate indemnification agreement with the Company consistent with the forgoing sentences on terms reasonably acceptable to the Board. 

5.9 Qualified Small Business Stock. The Company shall use commercially reasonable efforts to cause the shares of Preferred Stock, as
well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Internal Revenue Code (the “Code”), to constitute “qualified small business stock” as defined in
Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the Company.
The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder, provided that the
Company shall only be required to comply with the provisions of this sentence if the shares of Preferred Stock, or any shares into which such shares of Preferred Stock are converted, qualify as “qualified small business stock” as defined
in Section 1202(c) of the Code. In addition, within twenty (20) business days after any Investor’s written request therefor, the Company shall, at its option, either (i) deliver to such Investor a written statement indicating
whether (and what portion of) such Investor’s interest 

  
 - 21 - 

 
in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the
Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in
Section 1202(c) of the Code. 
 5.10 Indemnification Matters. The Company hereby acknowledges that one (1) or more of the
directors nominated to serve on the Board by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of
their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Investor Director are primary and any
obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the full amount of expenses
incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally permitted and as required by
the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors, and,
(c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company
further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall affect the foregoing and
the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor Directors and the Investor
Indemnitors are intended third-party beneficiaries of this Section 5.9 and shall have the right, power and authority to enforce the provisions of this
Section 5.9 as though they were a party to this Agreement. 
 5.11 Termination of Covenants. The covenants
set forth in this Section 5, except for Section 5.9, shall terminate and be of no further force or effect (i) immediately before the consummation of the Company’s Qualified Initial Public
Offering, as such term is defined in the Restated Certificate, or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation
Event, as such term is defined in the Restated Certificate, whichever event occurs first. 
 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) (i) by an
Investor to a transferee of Registrable Securities that (1) is an Affiliate of such Investor; (2) is such Investor’s Immediate Family Member or a trust for the benefit of such Investor or one or more of the Immediate Family Members of
such Investor; or (3) after such transfer, holds at least 2,500,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations), and (ii) by a Key Holder
to a transferee of Key Holder Registrable Securities that (1) is an Affiliate 

  
 - 22 - 

 
of such Key Holder; (2) is such Key Holder’s Immediate Family Member or a trust or other entity established for the benefit of such Key Holder or one or more of the Immediate Family
Members of such Key Holder; or (3) after such transfer, holds at least 900,000 shares of Key Holder Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations);
provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities or Key Holder Registrable Securities, as
the case may be, with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the
provisions of Section 2.11, with respect to the Registrable Securities or Key Holder Registrable Securities, as the case may be, so transferred to such transferee. For the purposes of determining the number of shares of
Registrable Securities or Key Holder Registrable Securities, as the case may be, held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of an Investor or Key Holder, as the case may be; (2) who is an
Immediate Family Member of an Investor or Key Holder, as the case may be; or (3) that is a trust or other entity established for the benefit of an individual Investor or Key Holder, as the case may be, or an Immediate Family Member of an
individual Investor or Key Holder, as the case may be, shall be aggregated together and with those of the transferring Investor or Key Holder, as the case may be; provided further that all transferees who would not qualify individually for
assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The
terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed
in accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6.3 Counterparts; Facsimile. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. This Agreement may also be executed and delivered by facsimile signature, electronic mail (including pdf) or other transmission method and in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 6.4 Titles and Subtitles. The
titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. 

6.5 Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed
effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during
normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day

  
 - 23 - 

 
after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification
of receipt. All communications shall be sent to the respective parties at their email addresses, facsimile numbers or addresses as set forth on Schedule A hereto, or, in the case of a permitted assignee of a Holder pursuant
to Section 6.1, to such permitted assignee’s email address, facsimile number or address as set forth in the written instrument delivered by such permitted assignee to the Company pursuant to
Section 6.1. If notice is given to the Company, it shall be sent to Vedantra Pharmaceuticals, Inc., One Kendall Square Bldg. 1400 West, Suite 14303, Cambridge, MA 02139, Attn: Gregory Berk, MD, President, with a copy to
Morgan, Lewis & Bockius LLP, 1 Federal Street, Boston, MA 02110, Attn: John J. Concannon III. 
 6.6 Amendments and Waivers.
This Agreement may be amended or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the
holders of a majority of the Registrable Securities, including the holders of a majority of the Series A Preferred Stock and holders of a majority of the Series B Preferred Stock then outstanding; provided that that (x) subject to the
provisions of clause (y) below, the rights and obligations of the Key Holders under this Agreement may not be amended, terminated or waived without the written consent of those Key Holders that hold a majority of the shares of Common Stock held
by all Key Holders, unless such amendment, termination, or waiver applies to the Key Holders and the Investors in the same fashion, and (y) the rights of any party to this Agreement may be waived by such party on its own behalf, without the
consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such
amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors
in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). The Company shall give prompt notice of any amendment
or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6
shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed
as a further or continuing waiver of any such term, condition, or provision. 
 6.7 Severability. In case any one or more of the
provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal,
or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

  
 - 24 - 

 6.9 Subsequent Investors. Any Subsequent Investor may become a party to this
Agreement by such Subsequent Investor and the Company executing and delivering either a counterpart signature page to this Agreement, and thereafter such Subsequent Investor shall be deemed to be an “Investor” for all purposes hereunder.

 6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding
and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement,
the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

6.11 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or
to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law
or otherwise afforded to any party, shall be cumulative and not alternative. 
 6.12 Dispute Resolution. The parties (a) hereby
irrevocably and unconditionally submit to the jurisdiction of the state courts of the State of Delaware and to the jurisdiction of the United States District Court for the District of the State of Delaware for the purpose of any suit, action or
other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of the State of Delaware or the United States
District Court for the District of the State of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the
jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that
this Agreement or the subject matter hereof may not be enforced in or by such court. 
 6.13 WAIVER OF JURY TRIAL. EACH PARTY HEREBY
WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION AGREEMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE),
BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND
REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

  
 - 25 - 

 6.14 Acknowledgment. The Company acknowledges that the Investors are in the business
of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company.
Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

[Remainder of Page Intentionally Left Blank] 

  
 - 26 - 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	VEDANTRA PHARMACEUTICALS, INC.

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	KEY HOLDERS:

 
			
		
	Signature:	 	  

 
			
	Name:	 	Satish Jindal
		
	Signature:	 	  

	Name:	 	Darrell Irvine
	
	MAXIM PARTNERS LLC

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 [Signature Page to
Amended and Restated Investors Rights Agreement] 

 [ENTITY INVESTOR SIGNATURE PAGE] 

 

			
	  

	Entity Name

 
			
		
	By:	 	  

 
			
	Name:	 	
	Title:	 	

  
 [Signature Page to
Amended and Restated Investors Rights Agreement] 

 [INDIVIDUAL INVESTOR SIGNATURE PAGE] 

 

	
	  

	Name:

  
 [Signature Page to
Amended and Restated Investors Rights Agreement] 

 SCHEDULE A 

INVESTORS 
 Name and
Address 
  

			
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 SCHEDULE B 

KEY HOLDERS 
 Name
and Address 
  

			
	Satish Jindal	  	c/o Vedantra Pharmaceuticals, Inc.
		  	One Kendall Square Bldg. 1400 West
		  	Suite 14303
		  	Cambridge, MA 02139
		
	Darrell Irvine	  	c/o Vedantra Pharmaceuticals, Inc.
		  	One Kendall Square Bldg. 1400 West
		  	Suite 14303
		  	Cambridge, MA 02139
		
	MAXIM PARTNERS LLC	  	c/o Maxim Group, LLC
		  	405 Lexington Avenue, 2nd Floor
		  	New York, NY 10174

 ELICIO THERAPEUTICS, INC. 

OMNIBUS AMENDMENT 
 This
Omnibus Amendment (the “Amendment”) is entered into as of September 30, 2019 by and among Elicio Therapeutics, Inc., a Delaware corporation (f/k/a Vedantra Pharmaceuticals, Inc.) (the “Company”), and the
requisite stockholders to each of the Investor Agreements (as defined below). 
 Recitals 

A. The Company is a party to that certain Investors’ Rights Agreement, dated August 30, 2018, with the stockholders listed therein (the
“Rights Agreement”); 
 B. The Company is a party to that certain Right of First Refusal and
Co-Sale Agreement, dated August 30, 2018, with the stockholders listed therein (the “Co-Sale Agreement”); 

C. The Company is a party to that certain Voting Agreement, dated August 30, 2018, with the stockholders listed therein (the “Voting
Agreement” and together with the Rights Agreement and the Co-Sale Agreement, the “Investor Agreements”); 

D. The Company desires to sell and issue shares of its Series B Preferred Stock, $0.001 par value per share (the “Series B Preferred Stock”),
pursuant to the Series B Preferred Stock Purchase Agreement dated as of even date herewith (the “2019 Series B Purchase Agreement”) to the purchasers listed on Exhibit A thereto and any other purchasers purchasing shares of
Series B Preferred Stock in a Closing after the Initial Closing (as such terms are defined in the 2019 Series B Purchase Agreement) (collectively, the “New Purchasers”); 

E. The undersigned desire to amend each of the Investor Agreements in order to, among other things, provide that any New Purchaser who is not a party to the
Investor Agreements is a party thereto; and 
 F. The execution of this Amendment by the undersigned stockholders is sufficient to amend each of the
Investor Agreements as set forth herein pursuant to their respective terms. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties agree as follows: 
 Amendment 

 

	 	1.	 Amendments to Rights Agreement. In the Rights Agreement, 

 

	 	(i)	 the term “Company” is hereby amended to mean Elicio Therapeutics, Inc.; 

 

	 	(ii)	 the term “Purchase Agreement” shall mean (a) the Series B Preferred Stock Purchase
Agreement dated as of August 30, 2018 (the “2018 Series B Purchase Agreement”) with respect to the Investors who purchased shares of 

	 	
Series B Preferred Stock pursuant to such 2018 Series B Purchase Agreement and (b) the 2019 Series B Purchase Agreement with respect to the New Purchasers; 

 

	 	(iii)	 the term “Restated Certificate” shall mean the Restated Certificate as defined in the 2019
Series B Purchase Agreement; 

  

	 	(iv)	 upon execution and delivery of a counterpart signature page to the Rights Agreement by each New Purchaser, such
New Purchaser shall be deemed an “Investor” for all purposes thereunder and the list of Investors listed on Schedule A shall be deemed updated include such New Purchaser; and 

 

	 	(v)	 in Section 5.4, the notice recipient is changed from Gregory Berk, MD, President, to Robert Connelly,
Chief Executive Officer. 

  

	 	2.	 Amendments to Co-Sale Agreement. In the Co-Sale Agreement, 

 (i) the term “Company” is hereby
amended to mean Elicio Therapeutics, Inc.; 
 (ii) the term “Purchase Agreement” shall mean (a) the
2018 Series B Purchase Agreement with respect to the Investors who purchased shares of Series B Preferred Stock pursuant to such 2018 Series B Purchase Agreement and (b) the 2019 Series B Purchase Agreement with respect to the New
Purchasers; 
 (iii) the term “Restated Certificate” shall mean the Restated Certificate as defined in the
2019 Series B Purchase Agreement 
 (iv) upon execution and delivery of a counterpart signature page to the Co-Sale Agreement by each New Purchaser, such New Purchaser shall be deemed an “Investor” for all purposes thereunder and the list of Investors listed on Schedule A shall be deemed updated to include each
such New Purchaser; and 
 (v) in Section 5.4, the notice recipient is changed from Gregory Berk, MD, President, to
Robert Connelly, Chief Executive Officer. 
  

	 	3.	 Amendments to Voting Agreement. In the Voting Agreement, 

 

	 	(i)	 the term “Company” is hereby amended to mean Elicio Therapeutics, Inc.; 

 

	 	(ii)	 the term “Purchase Agreement” shall mean (a) the 2018 Series B Purchase Agreement
with respect to the Investors who purchased shares of Series B Preferred Stock pursuant to such 2018 Series B Purchase Agreement and (b) the 2019 Series B Purchase Agreement with respect to the New Purchasers; 

 

	 	(iii)	 the term “Restated Certificate” shall mean the Restated Certificate as defined in the 2019
Series B Purchase Agreement; 

	 	(iv)	 upon execution and delivery of an Adoption Agreement (as defined in the Voting Agreement), each New Purchaser
shall be deemed an “Investor” for all purposes thereunder and the list of Investors listed on Schedule A shall be deemed updated to include each such New Purchaser; and 

 

	 	(v)	 in Section 7.6, the notice recipient is changed from Gregory Berk, MD, President, to Robert Connelly,
Chief Executive Officer. 

 IN WITNESS WHEREOF, the parties have executed this Omnibus Amendment as of the date first
written above. 
  

			
	COMPANY:
	
	ELICIO THERAPEUTICS, INC.

 
			
		
	By:	 	  

 
			
	Name:	 	Robert Connelly
	Title:	 	Chief Executive Officer
	Address:	 	One Kendall Square
		 	Building 1400W, Suite B14303
		 	Cambridge, MA 02139

 
	
	KEY HOLDERS:
	
	  

	
	  

	
	  

 
			
	INVESTOR:

 
			
		
	By:	 	  

 
			
		
	Name:	 	  

 
			
		
	Title:	 	  

 
			
		
	Address:	 	
	  

	  

	  

 
			
	INVESTOR:

 
			
		
	By:	 	  

 
			
		
	Name:	 	  

 
			
		
	Title:	 	  

 
			
		
	Address:EX-4.3

 Exhibit 4.3 

[Vedantra Pharmaceuticals, Inc.] 
 One Kendall Square 

1400 West, Suite 14303 
 Cambridge, MA 02139 

August 24, 2018 
 Clal Biotechnology Industries
Ltd. 
 132 Menachem Begin Road, Azrieli Center, Triangular Tower, 45th floor, Tel Aviv 

Re: Information Rights 

This letter confirms Vedantra Pharmaceuticals, Inc. (the “Company”) agreement to provide Clal Biotechnology Industries Ltd.
(the “Shareholder”) with certain information rights set forth in this letter agreement (this “Agreement”), subject to the terms set forth herein. 

Effectiveness of Rights. The Shareholder shall have the rights set forth in Sections 0 and 0 of this Agreement until
neither the Shareholder nor any company that controls the Shareholder is required to issue immediate and periodic reports pursuant to the Israeli Securities Law, 5728-1968 and/or the Securities Exchange Act of 1934 (together “Securities
Law” and the “Rights Period”, respectively). 
 Rights to Certain Financial Information. 

During the Rights Period, the Company shall deliver to the Shareholder: 

(i) Annual financial statements of the Company (including a balance sheet, statement of income, statement of shareholders equity, statement
of cash flow and related notes to the financial statements as well as subsequently even letters for the dates designated by the Shareholder) in respect of each fiscal year, signed by the Company, audited by a reputable accounting firm and
accompanied by a customary signed opinion of such firm within seven (7) days from the approval of such financial statements by the Company’s board of directors but in any event within sixty (60) days after the end of such fiscal year
of the Company. In addition, the Company shall deliver to the Shareholder the first draft of the above within fifty (50) days after the end of such fiscal year and subsequent drafts thereof prior to furnishing the signed financial statements;

 (ii) Quarterly financial statements of the Company in respect of each of the first three (3) fiscal quarters of each fiscal year of
the Company (including a balance sheet, statement of income, statement of shareholders equity and statement of cash flow and related notes to the financial statements as well as subsequently even letters for the dates designated by the Shareholder),
signed by the company and un-audited but reviewed by a reputable accounting firm, and accompanied by a customary signed review report of such firm, within seven (7) days from the approval of such
financial statements by the Company’s board of directors but in any event within thirty five (35) days following the end of such fiscal quarter of the Company. In addition, the Company shall deliver to the Shareholder the drafts of the
above within thirty (30) days following the end of such fiscal quarter prior to furnishing the signed financial statements; and 

(iii) Consent letters from the accountants and appraisals (insofar as the Company’s financial statements include a valuation) for the
inclusion thereof in the Shareholder’s filings or financial statements. 
 Any other information and/or documentation reasonably
required by the Shareholder to enable it to duly prepare its audited and non-audited consolidated financial statement (both annual and 

 
quarterly) and other required reports, including such information required in order to make the adjustments in accordance with International Financial Reporting Standards (IFRS), as issued by the
International Accounting Standards Board; and 
 All financial statements and other information provided pursuant to this Section 0
shall be prepared (to the extent applicable) in accordance with generally accepted accounting principles (“GAAP”) and, to the extent required, audited by a firm of Independent Certified Public Accountants. Such financial statements
and other information shall reflect any adjustments or modifications reasonably requested by the Shareholder, which are necessary for the Shareholder to comply with accounting standards and reporting requirements applicable to it under the
Securities Law. 
 Rights to Other Information. 

During the Rights Period, in the event that information with respect to the Company which is, required to be disclosed under the Securities
Law (including but not limited to: any immediate report of the Shareholder, in any periodic report of the Shareholder or any prospectus/shelf reports or similar document prepared in connection with any public offerings of any kind of the
Shareholder) (“Material Information”), then the Company shall provide such Material information to the Shareholder within a reasonable period to enable the Shareholder to comply with its reporting obligations under the Securities
Law. 
 During the Rights Period, in the event that the Company and/or the Shareholder become aware of any Material Information relating to
the Company, then the Company will provide to the Shareholder any such Material Information in order for the Shareholder to comply with its disclosure obligations under the Securities Law. 

The obligations of the Company under Sections 0 and 0 above shall be solely to the extent that (x) providing such information may not
jeopardize the Company’s attorney-client privilege or cause the Company or any subsidiary thereof to be in violation of any applicable law, and (y) the specific information which is required to be delivered to the Shareholder under this
Section 00 does not relate to specific events, occurrences or circumstances with respect to which there is a conflict of interest between the Company and the Shareholder. 

The Company will send the Shareholder a written notice with a description of the Material Information (including all the relevant facts) and
the Shareholder shall provide a draft of its proposed disclosure to the Company in advance of such disclosure so that, to the extent reasonably possible, the Company has a reasonable period of time to review and comment on such disclosure. The
Shareholder shall exert reasonable efforts to revise its disclosure on matters relating to the Company based on any comments provided by the Company to such draft proposed disclosure. 

The Shareholder shall use reasonable efforts, in the event that disclosure under the Securities Law is required with respect to information
provided by the Company under this Section 0, to limit the disclosure to the minimum scope necessary. 
 During the Rights Period, you
shall cooperate with us in order to assist us in meeting our obligations under the US SOX and/or Israeli SOX. 
 Successors and
Assigns. The rights and obligations under this Agreement may not be assigned by either party hereto without the consent of the other party. 

Governing Law; Jurisdiction. This Letter and any controversy arising out of or relating to this Letter shall be governed by and
construed in accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

 Counterparts; Facsimile. This Agreement may be executed and delivered by facsimile
signature and in two or more counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. 

Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 Notices. All notices and other communications given or made pursuant to this Agreement
shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by electronic mail if sent during normal business hours of the recipient, and if sent after such normal
business hours, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after the business day of deposit with a
nationally recognized overnight courier, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as kept on record with the Company, or to such email
address, facsimile number or address of a party as subsequently modified by such party’s written notice given in accordance with this paragraph 0. 

Consent Required to Amend or Waive. This Agreement may be amended or modified and the observance of any term hereof may be waived
(either generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed by the Company and the Shareholder. 

Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any
other provision hereof. 
 Entire Agreement. This Agreement constitutes the entire understanding and agreement between the parties
hereto with respect to the subject matter hereof, and any other written or oral agreement, understanding or arrangement relating to the subject matter hereof existing between the parties are expressly canceled and shall have no further force and
effect. The above notwithstanding, nothing herein shall derogate from the Shareholder’s rights under the Investors’ Rights Agreement. 

[Signature Page Follows] 

 
			
	Sincerely,
	
	VEDANTRA PHARMACEUTICALS, INC.

 
			
		
	By:	 	 /s/ Daniel Geffken

			
	Name:	 	Daniel Geffken
	Title:	 	CFO

 ACKNOWLEDGED AND ACCEPTED: 
  

			
	CLAL BIOTECHNOLOGY INDUSTRIES LTD.

			
		
	By:	 	  

			
		
	Name:	 	  

			
		
	Title:	 	  

 [Signature Page of Letter Agreement re. Information Rights; August 2018]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]